Related references
Note: Only part of the references are listed.
Article
Multidisciplinary Sciences
Leander Witte et al.
Summary: The emergence of SARS-CoV-2 variants with neutralizing antibody resistance mutations has led to waves of infection. However, repeated exposure to antigens has also resulted in the production of broadly neutralizing antibodies against these variants. Through their study, Witte et al found that specific substitutions in the spike protein of SARS-CoV-2 enable the acquisition of resistance to broadly neutralizing antibodies. These findings highlight the importance of understanding the interactions between new and old substitutions in the development of antibody escape.
NATURE COMMUNICATIONS
(2023)
Review
Immunology
Yanjia Chen et al.
Summary: This article summarizes neutralizing antibodies targeting four key regions of the SARS-CoV-2 spike protein, which are important for developing antibody therapeutics and designing next-generation vaccines.
NATURE REVIEWS IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Wanwisa Dejnirattisai et al.
Summary: On November 24, 2021, the sequence of a new SARS-CoV-2 variant, Omicron-B.1.1.529, was announced. Compared to previous variants, Omicron has a higher number of mutations in the Spike (S) protein. Serum neutralization of Omicron by individuals vaccinated or previously infected with Alpha, Beta, Gamma, or Delta variants is significantly reduced or ineffective. Third vaccine doses can boost neutralization titers against Omicron, and high titers are observed in both vaccinated individuals and those infected with the Delta variant. Most potent monoclonal antibodies and antibodies under development are unable to effectively neutralize Omicron due to mutations in its Spike protein. Omicron has structural changes compared to earlier viruses and utilizes mutations that enhance its binding to ACE2, allowing for immune escape. This results in a large number of mutations in the ACE2 binding site and a rebalancing of receptor affinity similar to earlier pandemic viruses.
Article
Biochemistry & Molecular Biology
Zhen Cui et al.
Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly worldwide due to its increased fitness, with spike structures that maintain stability for receptor recognition but compromise viral fusion efficiency. By altering amino acids and structures, it evades recognition by most antibodies, facilitating immune escape. The research sheds light on conserved regions for the development of broad-spectrum vaccines.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.
Article
Multidisciplinary Sciences
Yunlong Cao et al.
Summary: The Omicron variant of SARS-CoV-2 contains 15 mutations in the receptor-binding domain, leading to evasion of over 85% of tested neutralizing antibodies. Different epitope groups of neutralizing antibodies are affected to varying degrees by single mutations of Omicron. Antibodies targeting the conserved region of sarbecovirus remain most effective against Omicron.
Article
Multidisciplinary Sciences
Wanchao Yin et al.
Summary: The structures of the Omicron spike trimer and its interactions with ACE2 and an anti-Omicron antibody are reported. Most mutations in Omicron are located on the spike protein surface, altering binding to many existing antibodies. Compensating mutations in the ACE2-binding site enhance binding to ACE2. The therapeutic antibody JMB2002 maintains neutralizing activity against Omicron and inhibits ACE2 binding.
Article
Multidisciplinary Sciences
Young-Jun Park et al.
Summary: Understanding broadly neutralizing sarbecovirus antibody responses is crucial for developing countermeasures against SARS-CoV-2 variants and future sarbecoviruses. The human monoclonal antibody S2K146 has been found to broadly neutralize ACE2-binding viruses and shows potential for clinical development. Conserved ACE2-binding residues could be leveraged for developing vaccines that elicit broad immunity.
Article
Cell Biology
David R. Martinez et al.
Summary: Severe acute respiratory syndrome coronaviruses (SARS-CoVs), including SARS-CoV-2 variants, can cause deadly infections. A human antibody called DH1047 has been shown to neutralize SARS-CoV and various coronaviruses, and protect against SARS-CoV-2 B.1.351 infection in mice. The study suggests that DH1047 could be a broadly protective antibody and a potential target for a universal sarbecovirus vaccine.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
News Item
Infectious Diseases
Sharmila Devi
LANCET INFECTIOUS DISEASES
(2022)
Letter
Medicine, General & Internal
Annika Roessler et al.
Summary: Although some antibodies generated in persons recovering from infection with the omicron variant show cross-reactivity, a group of unvaccinated individuals were found to have largely ineffective antibodies against other viral strains.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cell Biology
Zezhong Liu et al.
Summary: The newly identified antibody XG014 demonstrates potent neutralizing activity against beta-coronaviruses, with a unique recognition mode and conservation epitope, making it a potential therapeutic candidate for pan-beta-coronavirus treatment. Its single-dose administration shows efficacy in protecting and treating SARS-CoV-2 infection in vivo.
Article
Cell Biology
Kathryn Westendorf et al.
Summary: A monoclonal antibody named LY-CoV1404 has been successfully isolated, which demonstrates highly potent neutralization against multiple variants of the SARS-CoV-2 virus. The binding site of LY-CoV1404 remains relatively conserved, allowing it to maintain its activity. This finding suggests that LY-CoV1404 has the potential to be an effective therapeutic agent against all known variants.
Article
Multidisciplinary Sciences
Anna-Lena Mader et al.
Summary: SARS-CoV-2 Omicron is a pandemic variant of concern with mutations in the receptor-binding domain and reduced serum neutralization against it. Booster vaccination can enhance the response, but it is still lower compared to the response against the Wuhan strain. However, some antibodies can still bind and potentially be used in the prevention and treatment of Omicron-induced COVID-19.
Article
Multidisciplinary Sciences
Ryota Otsubo et al.
Summary: This study investigated neutralizing antibodies against new variants of the coronavirus and identified two antibodies that were able to neutralize the wild-type virus and the Delta variant, but not the Omicron variant. One of the antibodies targeted the N-terminal domain of the S1 subunit and inhibited S1/S2 cleavage, thus preventing viral entry. The results suggest that neutralizing antibodies targeting S1/S2 cleavage inhibition may have cross-reactivity against multiple virus variants.
SCIENTIFIC REPORTS
(2022)
Article
Multidisciplinary Sciences
Yunlong Cao et al.
Summary: Omicron sublineages BA.2.12.1, BA.4 and BA.5 have higher transmissibility and increased evasion of neutralizing antibodies compared to the BA.2 lineage. They exhibit similar binding affinities to the ACE2 receptor as BA.2. BA.1 infection after vaccination boosts humoral immune memory against wild-type SARS-CoV-2, but these antibodies are largely evaded by BA.2 and BA.4/BA.5 variants.
Article
Immunology
John E. Bowen et al.
Summary: This study demonstrates that vaccines containing prefusion-stabilizing S mutations can induce enhanced antibody responses in humans, particularly in recognition of the S and S1 subunit. Antibody binding to prefusion S and S1 correlates positively and equivalently with neutralizing activity, with S1-directed antibodies being crucial for plasma neutralization. The study also shows that neutralizing activity is predominantly directed at the S1 subunit and variant cross-neutralization is mediated solely by receptor binding domain-specific antibodies.
SCIENCE IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Meng Yuan et al.
Summary: Therapeutic antibody ADG20 shows effectiveness in neutralizing SARS-CoV-2 variants, including Omicron, by binding to two different sites on the virus. This study has implications for the design of universal vaccines and therapeutic antibodies.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Multidisciplinary Sciences
Jun Siong Low et al.
Summary: Researchers have isolated seven monoclonal antibodies that can bind to spike proteins of all human-infecting coronaviruses, including SARS-CoV-2. Some of these antibodies show broad neutralizing activity against different types of coronaviruses and can also neutralize Omicron BA.1 and BA.2 viruses, reducing viral burden and pathology.
Article
Cell Biology
Victoria Stalls et al.
Summary: This study determines the cryoelectron microscopy structures of the Spike (S) protein of the Omicron BA.2 sub-lineage of the SARS-CoV-2 virus and compares it with the BA.1 sub-lineage. The BA.2 S protein exhibits tighter packing and improved thermostability due to mutations in the receptor-binding domain (RBD). The closed state of BA.2 S enhances RBD interactions and shows reduced accessibility of the fusion peptide to antibodies compared to BA.1.
Article
Multidisciplinary Sciences
Sho Iketani et al.
Summary: The identification of the Omicron variant of SARS-CoV-2 in Botswana in November 2021 sparked concern due to the spike protein alterations that could potentially evade antibodies. Further studies showed that the Omicron sublineages, BA.1+R346K and BA.2, are antigenically similar to the wild-type virus and pose similar risks to the effectiveness of current vaccines. BA.2 also demonstrated resistance to many neutralizing monoclonal antibodies, highlighting the challenges in developing effective therapeutic options.
Review
Microbiology
Ben Hu et al.
Summary: This review summarizes the research progress on SARS-CoV-2 and COVID-19, including virology characteristics, pathogenesis, and recent advances in treatment methods. Furthermore, it discusses in detail the potential wildlife hosts and zoonotic origin of this emerging virus.
NATURE REVIEWS MICROBIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Alessandro Sette et al.
Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.
Article
Microbiology
Allison J. Greaney et al.
Summary: Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are key in neutralizing antibody responses, and a deep mutational scanning method was used to assess the impact of all amino-acid mutations in the RBD on antibody binding with 10 human monoclonal antibodies. The study identified the clustered escape mutations in different surfaces of the RBD that correspond to structurally defined antibody epitopes, showing that even antibodies targeting the same surface can have distinct escape mutations.
CELL HOST & MICROBE
(2021)
Article
Multidisciplinary Sciences
C. Garrett Rappazzo et al.
Summary: The engineered antibody ADG-2 shows enhanced neutralization breadth and potency against a wide range of sarbecoviruses, providing complete protection in SARS and COVID-19 mouse models. Structural and biochemical studies reveal that ADG-2 targets a highly conserved epitope through a unique angle of approach.
Article
Multidisciplinary Sciences
Pengfei Wang et al.
Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.
Article
Multidisciplinary Sciences
Supaporn Wacharapluesadee et al.
Summary: A study identified a SARS-CoV-2-related coronavirus (SC2r-CoV), RacCS203, in Rhinolophus acuminatus bats from Thailand, with 91.5% genome similarity to SARS-CoV-2, and demonstrated that sera obtained from bats and Malayan pangolin can neutralize SARS-CoV-2.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Deborah Delaune et al.
Summary: The study identified SARS-CoV-2 related coronaviruses in bats sampled in Cambodia, indicating a wider geographic distribution than previously reported. The findings suggest that Southeast Asia may be a key area to consider for future coronavirus surveillance.
NATURE COMMUNICATIONS
(2021)
Article
Cell Biology
Renhong Yan et al.
Summary: This study investigated the structural basis for the potent neutralizing activity of nAbs against SARS-CoV-2, finding that the bivalent binding of full-length IgG associates with more RBDs in the up conformation, leading to enhanced neutralization and shedding of the S1 subunit from the S protein. Comparing a large number of nAbs revealed common and unique structural features associated with their potent neutralizing activities.
Review
Biochemistry & Molecular Biology
Davide Corti et al.
Summary: Monoclonal antibodies have revolutionized the treatment of several human diseases, including cancer, autoimmunity, and infectious diseases. Lessons learned from the COVID-19 pandemic have paved the way for the development of more monoclonal antibody-based therapeutics.
Article
Biochemical Research Methods
Wei Yu et al.
Summary: The study utilized molecular dynamics simulation to investigate the binding mechanism of the CR3022 antibody against SARS-CoV and HCoV-19, revealing common conservative amino acids in both systems and highlighting the deficiency of crucial hydrogen bonds and salt bridges in the HCoV-19-RBD system, resulting in a loss of affinity.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
(2021)
Article
Multidisciplinary Sciences
M. Alejandra Tortorici et al.
Summary: The emergence of SARS-CoV-2 variants and recurrent spillovers of coronaviruses into the human population emphasize the need for broadly neutralizing antibodies to prevent future zoonotic infections. The human monoclonal antibody S2X259 has shown promising results in neutralizing various forms of SARS-CoV-2 and potentially zoonotic sarbecoviruses by inhibiting the binding of ACE2 to the receptor-binding domain. This antibody targets a key antigenic site and may guide the design of vaccines effective against all sarbecoviruses.
Article
Multidisciplinary Sciences
Tyler N. Starr et al.
Summary: An ideal therapeutic anti-SARS-CoV-2 antibody should have resistance to viral escape, activity against diverse sarbecoviruses, and provide high protection through viral neutralization and effector functions. Studies have found a trade-off between in vitro neutralization potency and breadth of sarbecovirus binding in SARS-CoV-2 antibodies targeting the RBD, but identified some antibodies with exceptional sarbecovirus breadth and resistance to SARS-CoV-2 escape.
Article
Medicine, General & Internal
Chee-Wah Tan et al.
Summary: Survivors of SARS-CoV-1 infection who received the BNT162b2 mRNA vaccine produced potent cross-clade pan-sarbecovirus neutralizing antibodies, capable of neutralizing various variants of concern and potential human-infecting coronaviruses, indicating the feasibility of a pan-sarbecovirus vaccine strategy.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Lingshu Wang et al.
Summary: The study identified four receptor binding domain-targeting antibodies with potent neutralizing activity against 23 variants, including two ultrapotent antibodies. Combinations of these antibodies reduced the in vitro generation of escape mutants, showing potential in mitigating resistance development.
Article
Multidisciplinary Sciences
Dora Pinto et al.
Summary: The study identified five monoclonal antibodies from COVID-19 convalescent individuals that cross-react with multiple betacoronavirus spike glycoproteins, with one antibody (S2P6) showing broad neutralization of viruses from three different subgenera. This antibody reduced viral burden in hamsters challenged with SARS-CoV-2 by inhibiting membrane fusion, providing a framework for the design of pan-betacoronavirus vaccines for broad protection.
Article
Cell Biology
Claudia A. Jette et al.
Summary: This study characterizes two class 4 anti-RBD antibodies derived from COVID-19 donors that exhibit breadth and potent neutralization of zoonotic coronaviruses and SARS-CoV-2 variants. These antibodies work by occluding the ACE2 binding site and reducing sensitivity to variations in the protein structure.
Article
Cell Biology
Federico Bertoglio et al.
Summary: Researchers have developed a human neutralizing antibody against SARS-CoV-2, which shows promising efficacy in animal models and is currently undergoing clinical trials for the treatment of moderate to severe COVID-19. The antibody binds to the receptor-binding domain (RBD) of the spike protein to inhibit the virus, and is not affected by many known RBD mutations.
Article
Immunology
Benjamin Israelow et al.
Summary: Research demonstrates that both humoral and cellular immunity play a role in clearing SARS-CoV-2, and convalescent mice or mice vaccinated with mRNA are protected from infection with both the wild type virus and the B.1.351 variant. This protection is mainly mediated by antibody response rather than cellular immunity.
SCIENCE IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Ester Lopez et al.
Summary: This study introduces a new rapid multiplex assay for measuring SARS-CoV-2 antibodies that can evaluate multiple RBD natural variants, filling a major gap in SARS-CoV-2 research and providing a method for selecting complementary monoclonal antibody candidates and rapidly identifying immune escape to emerging RBD variants following vaccination or natural infection.
Article
Multidisciplinary Sciences
Alexander A. Cohen et al.
Summary: The study developed nanoparticles displaying the receptor binding domain (RBD) of SARS-CoV-2 and other animal coronaviruses, which induced cross-reactive antibody responses in mice. Immunization with mosaic RBD nanoparticles resulted in superior neutralization of heterologous viruses, providing a potential strategy for simultaneous protection against multiple coronaviruses.
Article
Multidisciplinary Sciences
Peng Zhou et al.
Article
Multidisciplinary Sciences
Dora Pinto et al.
Article
Multidisciplinary Sciences
Tommy Tsan-Yuk Lam et al.
Article
Biochemistry & Molecular Biology
Tyler N. Starr et al.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Article
Biotechnology & Applied Microbiology
Chee Wah Tan et al.
NATURE BIOTECHNOLOGY
(2020)
Article
Multidisciplinary Sciences
Meng Yuan et al.
Review
Multidisciplinary Sciences
Florian Krammer
Article
Multidisciplinary Sciences
Christopher O. Barnes et al.
Article
Microbiology
Nicholas C. Wu et al.
Review
Medicine, Research & Experimental
Marco Tuccori et al.
Article
Biochemical Research Methods
Dorothee Liebschner et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY
(2019)
Article
Biochemical Research Methods
Dimitry Tegunov et al.
Article
Chemistry, Multidisciplinary
Jasenko Zivanov et al.
Article
Biochemistry & Molecular Biology
Thomas D. Goddard et al.
Article
Biochemistry & Molecular Biology
Andrew Waterhouse et al.
NUCLEIC ACIDS RESEARCH
(2018)
Article
Biochemical Research Methods
Ali Punjani et al.
Article
Biochemistry & Molecular Biology
Alexis Rohou et al.
JOURNAL OF STRUCTURAL BIOLOGY
(2015)
Article
Biochemistry & Molecular Biology
Xavier Robert et al.
NUCLEIC ACIDS RESEARCH
(2014)
Article
Biochemistry & Molecular Biology
Sjors H. W. Scheres
JOURNAL OF STRUCTURAL BIOLOGY
(2012)
Article
Medicine, General & Internal
Ali Moh Zaki et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2012)
Article
Biochemistry & Molecular Biology
Fabian Sievers et al.
MOLECULAR SYSTEMS BIOLOGY
(2011)
Article
Biochemical Research Methods
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
(2010)
Article
Biochemical Research Methods
Kenneth Smith et al.
Article
Medicine, General & Internal
Jan ter Meulen et al.
Article
Multidisciplinary Sciences
WD Li et al.
Article
Biochemistry & Molecular Biology
DN Mastronarde
JOURNAL OF STRUCTURAL BIOLOGY
(2005)
Article
Chemistry, Multidisciplinary
EF Pettersen et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY
(2004)
